



Ribosomal Antibiotics: Recent Advances

Guest Editor:

Dr. Miri Krupkin

Department of Structural
Biology, Stanford University
School of Medicine, Stanford, CA
94305, USA

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editor

Dear Colleagues,

The discovery and use of antibiotics have improved both longevity and quality of life. Ribosomal antibiotics comprise a major class of clinically available antibiotics, targeting more than a dozen different sites on both ribosomal subunits.

This Issue welcomes manuscript submissions. Specifically, work from the following fields of research is especially encouraged:

- Resistance mechanisms of ribosomal antibiotics, including RNA modifications;
- Organic and enzymatic synthesis and modification of ribosomal antibiotics;
- In vitro and in situ structures of ribosomal antibiotics;
- Discovery of new ribosomal antibiotics using both classical natural products and bioinformatics approaches;
- Ribosomal antibiotics in producing bacteria;
- Pathogen specificity of ribosomal antibiotics;
- Ribosomal antibiotics in women's and children's health;
- Clinical studies of ribosomal antibiotics and nosocomial pathogens;
- Ribosomal antibiotics and their environmental impact;
- Ribosomal antibiotics use in animals;
- Ribosomal antibiotics in teaching and education.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi